Blood pressure drug may have added benefit

Feb 14, 2008

University of Kentucky researchers have discovered a possible added benefit of a novel new drug that lowers blood pressure.

Dr. Lisa Cassis and Dr. Alan Daugherty found in animal studies that aliskiren not only lowered blood pressure but also significantly reduced artery-clogging lesions that are the leading cause of heart attack and stroke, the top cause of death worldwide.

"In my many years of atherosclerosis research, this is one of the most striking effects I have seen on preventing the disease under experimental conditions," Daugherty said. "This contributes to our knowledge of the underlying disease that causes heart attack and stroke."

Cassis is director of the UK Graduate Center for Nutritional Sciences and Daugherty is director of the UK Cardiovascular Research Center. Their work will appear in the March issue of the Journal of Clinical Investigation and is available online beginning today at www.jci.org .

Aliskiren, marketed under the brand name Tekturna by pharmaceutical manufacturer Novartis, is the first new class of blood pressure medication approved by the FDA in more than a decade. Approved a year ago, it acts differently than any other medication currently on the market by inhibiting renin, an enzyme that is primarily produced in the kidneys. Renin is the first step in the synthesis of one of the most important molecules in blood pressure regulation.

"Our data shows that renin inhibition is an effective approach to both lowering blood pressure and directly inhibiting atherosclerosis. It will be interesting to determine whether this approach is more effective than the two other commonly used classes of drugs in the angiotensin system; ACE inhibitors and ARBs," Daugherty said.

Source: University of Kentucky

Explore further: Added benefit of vedolizumab is not proven

add to favorites email to friend print save as pdf

Related Stories

Atherosclerosis solution is likely many years away

Feb 21, 2008

While advances have been made in understanding how genetics, metabolism of HDL and LDL cholesterol, the inflammatory process, blood clots, and blood pressure regulation all play a part in the atherosclerosis disease process, ...

Recommended for you

Added benefit of vedolizumab is not proven

17 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0